NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Show more
Location: Gooimeer 2-35, Naarden, 1411 DC, Netherlands | Website: https://www.newamsterdampharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
2.085B
52 Wk Range
$14.06 - $27.29
Previous Close
$18.57
Open
$18.46
Volume
1,152,089
Day Range
$18.06 - $18.70
Enterprise Value
1.277B
Cash
808.5M
Avg Qtr Burn
-35.11M
Insider Ownership
0.39%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Obicetrapib + ezetimibe Details Dyslipidemia, Hypercholesterolemia | Phase 3 Data readout | |
Obicetrapib Details Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease | Phase 3 Update | |
Phase 2a Data readout |